Ho DH - Search Results

1

Phase I trial of FK973: description of a delayed vascular leak syndrome.

Pazdur R, Ho DH, Daugherty K, Bradner WT, Krakoff IH, Raber MN. Pazdur R, et al. Among authors: ho dh. Invest New Drugs. 1991 Nov;9(4):377-82. doi: 10.1007/BF00183587. Invest New Drugs. 1991. PMID: 1804817 Clinical Trial.

2

Phase I trial of a 72-h continuous-infusion schedule of fazarabine.

Amato R, Ho D, Schmidt S, Krakoff IH, Raber M. Amato R, et al. Cancer Chemother Pharmacol. 1992;30(4):321-4. doi: 10.1007/BF00686303. Cancer Chemother Pharmacol. 1992. PMID: 1379523 Clinical Trial.

3

Clinical pharmacology of 11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11-diazatetracyclo (7.4.1.0(2,7).0(10,12) tetradeca-2,4,6-trien-6,9-diyl diacetate (FK 973).

Ho DH, Pazdur R, Brown NS, Covington WP, Raber MN, Krakoff IH. Ho DH, et al. Anticancer Res. 1993 Mar-Apr;13(2):343-6. Anticancer Res. 1993. PMID: 8517646

4

Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.

Pazdur R, Lassere Y, Diaz-Canton E, Bready B, Ho DH. Pazdur R, et al. Among authors: ho dh. Invest New Drugs. 1997;15(2):123-8. doi: 10.1023/a:1005808822565. Invest New Drugs. 1997. PMID: 9220291 Clinical Trial.

5

Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities.

Pazdur R, Lassere Y, Diaz-Canton E, Bready B, Ho DH. Pazdur R, et al. Among authors: ho dh. Anticancer Drugs. 1996 Sep;7(7):728-33. doi: 10.1097/00001813-199609000-00002. Anticancer Drugs. 1996. PMID: 8949982 Clinical Trial.

6

Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.

Pazdur R, Lassere Y, Diaz-Canton E, Ho DH. Pazdur R, et al. Among authors: ho dh. Cancer Invest. 1998;16(3):145-51. doi: 10.3109/07357909809050028. Cancer Invest. 1998. PMID: 9541627 Clinical Trial.

7

Clinical pharmacology of combined oral uracil and ftorafur.

Ho DH, Covington WP, Pazdur R, Brown NS, Kuritani J, Newman RA, Raber MN, Krakoff IH. Ho DH, et al. Drug Metab Dispos. 1992 Nov-Dec;20(6):936-40. Drug Metab Dispos. 1992. PMID: 1362949 Clinical Trial.

8

Clinical pharmacology of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) following 72-hour infusion.

Ho DH, Brown N, Lin JR, Covington W, Newman RA, Raber M, Amato R, Schmidt S, Krakoff IH. Ho DH, et al. Drug Metab Dispos. 1991 May-Jun;19(3):643-7. Drug Metab Dispos. 1991. PMID: 1717216

9

Polyethylene glycol-L-asparaginase and L-asparaginase studies in rabbits.

Ho DH, Wang CY, Lin JR, Brown N, Newman RA, Krakoff IH. Ho DH, et al. Drug Metab Dispos. 1988 Jan-Feb;16(1):27-9. Drug Metab Dispos. 1988. PMID: 2894951

10

Depletion of patients' plasma tryptophan using tryptophan side-chain oxidase columns.

Ho DH, Covington WP, Wallerstein RO, Hester JP, Lin JR, Brown NS, Newman RA, Krakoff IH, Freireich EJ. Ho DH, et al. Cancer Invest. 1993;11(3):252-7. doi: 10.3109/07357909309024849. Cancer Invest. 1993. PMID: 8485647

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209 results

Search Page

Filters